This further advocates the mitigating role of rituximab in anti‐LGI1 encephalitis, especially in the relapsing cases, both in terms of improving mRS score and maintaining long‐term disease remission (Brown et al., 2014; Irani et al., 2014; Nepal et al., 2020). Here, LGI1 is linked to encephalitis.